Allspring Global Investments’s Arcutis Biotherapeutics ARQT Stock Holding History

Allspring Global Investments’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,114,111	Closed	-$12.3M	–	2697
2023 Q1	$12.3M	Buy	1,114,111 +47,260	+4%	+$684K	0.02%	728
2022 Q4	$15.8M	Buy	1,066,851 +338,487	+46%	+$5.91M	0.03%	657
2022 Q3	$13.9M	Buy	728,364 +98,610	+16%	+$2.23M	0.02%	667
2022 Q2	$13.4M	Buy	629,754 +20,106	+3%	+$412K	0.02%	698
2022 Q1	$11.7M	Sell	609,648 -7,952	-1%	-$135K	0.01%	834
2021 Q4	$12.8M	Buy	+617,600	New	+$12.3M	0.01%	846

Other funds holding ARQT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Allspring Global Investments's ARQT Position: Q2 2023 in Review

Allspring Global Investments sold out of Arcutis Biotherapeutics (ARQT) in Q2 2023, closing a stake of 1,114,111 shares — an estimated $12.3M sold.

Allspring Global Investments first reported a position in ARQT in Q4 2021 and held it in 6 quarters. The position peaked at $15.8M in Q4 2022. 136 funds tracked by Wall St. Rank hold ARQT as of Q2 2023.

Allspring Global Investments reported no remaining Arcutis Biotherapeutics position as of Q2 2023 after selling out during the quarter.
Allspring Global Investments sold 1,114,111 Arcutis Biotherapeutics shares in Q2 2023, an estimated $12.3M.
Allspring Global Investments first reported a position in Arcutis Biotherapeutics in Q4 2021 and held it in 6 quarters.
Allspring Global Investments's Arcutis Biotherapeutics position peaked at $15.8M in Q4 2022.
136 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2023.

Based on Allspring Global Investments's 13F filing for Q2 2023, filed 18 Jul 2023.